Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial DNA-directed RNA polymerase (RNAP) subunit beta' switch region is a critical structural hinge located at the base of the RNAP clamp, which facilitates the conformational changes necessary for DNA binding and transcription initiation (Mukhopadhyay et al., 2008, Cell). This region acts as a 'switch' that allows the enzyme to transition between an open state, which permits DNA entry into the active-site cleft, and a closed state, which secures the DNA for processive RNA synthesis (Belogurov et al., 2009, Nature). Because this region is highly conserved across diverse bacterial species and is essential for viability, it serves as a potent target for a class of antibiotics known as switch-region inhibitors (SRIs) (Srivastava et al., 2011, Curr Opin Microbiol). Drugs such as myxopyronin, corallopyronin, and fidaxomicin bind specifically to this pocket, preventing the necessary movement of the clamp and effectively halting the transcription process (Ebright, 2011, RNA Biol). This mechanism is distinct from that of rifamycins, which bind to the RNAP active-site channel, meaning that switch-region inhibitors remain effective against many rifampin-resistant bacterial strains, including Mycobacterium tuberculosis (Maffioli et al., 2017, Cell). Consequently, the beta' switch region is a focal point for the development of novel broad-spectrum antibacterial agents aimed at overcoming multi-drug resistance.
Inhibition of the conformational 'switch' movement required for the RNA polymerase clamp to close around DNA, thereby preventing the formation of a stable transcription initiation complex (Switch-region inhibition).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial DNA-directed RNA polymerase subunit beta' switch region (RNAP β′ switch region).